Blinded histopathological characterisation of POLE exonuclease domain‐mutant endometrial cancers: sheep in wolf's clothing
Histopathology2017Vol. 72(2), pp. 248–258
Citations Over TimeTop 11% of 2017 papers
Inge C. van Gool, Jef E H Ubachs, Ellen Stelloo, Cor D. de Kroon, Jelle J. Goeman, Vincent T.H.B.M. Smit, Carien L. Creutzberg, Tjalling Bosse
Abstract
A simple combination of morphological and immunohistochemical characteristics (tumour type, grade, peritumoral lymphocytes, MLH1, and p53 expression) can assist in prescreening for POLE exonuclease domain mutations in EC, increasing the probability of a mutation being detected from 7% to 33%. This facilitates the use of this important prognostic biomarker in routine pathology.
Related Papers
- → Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation(1991)618 cited
- → Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.(1991)237 cited
- → Developmental properties of induced buds from a nonbudding mutant of Hydra viridis(1981)3 cited
- → Isolation and characterization of a novelArabidopsis thatianamutant that requires a high concentration of boron(2004)
- Photosynthetic and Chlorophyll Fluorescence Characteristics of Xantha Type Rice Mutant(2007)